• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by vTv Therapeutics Inc.

    5/1/25 4:28:23 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTVT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001957337
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    vTv Therapeutics Inc.
    SEC File Number
    001-37524
    Address of Issuer
    3980 Premier Drive,
    Suite 310
    High Point
    NORTH CAROLINA
    27265
    Phone
    (336) 841-0300
    Name of Person for Whose Account the Securities are To Be Sold
    STEVEN TUCH
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    125825160.00319456405/01/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/15/2025Exercised SharesIssuerCheckbox not checked125804/15/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/29/2025100021500.00
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/24/2025100021500.00
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/22/2025100019000.20
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/10/20254007147.32
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/10/20253005417.16

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/01/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Steven L. Tuch

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VTVT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTVT

    DatePrice TargetRatingAnalyst
    2/18/2022$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $VTVT
    SEC Filings

    View All

    SEC Form 10-Q filed by vTv Therapeutics Inc.

    10-Q - vTv Therapeutics Inc. (0001641489) (Filer)

    8/12/25 4:09:52 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    8/12/25 4:05:11 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    6/12/25 4:23:03 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres, CEO and Exec Chairperson Sekhri Paul J bought $83,812 worth of shares (5,000 units at $16.76) (SEC Form 4)

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    11/19/24 4:31:06 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    •   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments. "The

    8/12/25 4:15:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

    HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041. "We are pleased with the outcome of the prosecution of this patent as it further strengthens the protection around cadisegliatin," s

    8/11/25 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

    HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced the first study participant has been randomized in the Company's CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment to insulin in adults with type 1 diabetes (T1D). Cadisegliatin is a potential first-in-class, oral, liver-selective glucokinase activator for T1D that has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and has been well-tolerated in over 500 subjects to date with up to six months

    8/7/25 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on vTv Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of vTv Therapeutics with a rating of Overweight and set a new price target of $5.00

    2/18/22 6:42:27 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    6/12/25 4:28:34 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Spiegelman Daniel K

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    6/12/25 4:28:17 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Akkaraju Srinivas

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    6/12/25 4:27:28 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Financials

    Live finance-specific insights

    View All

    vTv Therapeutics Announces Investment by CinRx Pharma

    HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC ("CinPax"), a subsidiary of CinRx Pharma, LLC ("CinRx"). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on November 22, 2022. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares of Class A Common Stock that become exercisable upon agreed vesting triggers (including FDA ap

    7/25/22 7:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by vTv Therapeutics Inc.

    SC 13G - vTv Therapeutics Inc. (0001641489) (Subject)

    11/12/24 10:40:28 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by vTv Therapeutics Inc. (Amendment)

    SC 13D/A - vTv Therapeutics Inc. (0001641489) (Subject)

    3/22/24 4:57:31 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by vTv Therapeutics Inc.

    SC 13D - vTv Therapeutics Inc. (0001641489) (Subject)

    3/5/24 7:52:29 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Leadership Updates

    Live Leadership Updates

    View All

    vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    •   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments. "The

    8/12/25 4:15:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

    HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time for the Company, which recently reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of

    5/19/25 9:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

    Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate de

    3/20/25 5:35:31 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care